Clinical and biochemical evaluation of HIV-related lipodystrophy in an ambulatory population from the hospital universitário cassiano Antonio de Morais, Vitória, ES, Brazil

Brazilian Journal of Infectious Diseases

Volumn 12, Issue 4, 2008, Pages 264-268

  Monnerat, Bruno Zanotelli ^a   Cerutti Jr , Crispim ^a,b   Caniçali, Sheila Cristina ^a   Motta, Tânia Reuter ^a  

^a Infectious Diseases Division   (Brazil)

^b FEDERAL UNIVERSITY OF ESPÍRITO SANTO   (Brazil)

Author keywords

AIDS; ARV therapy; Brazil; Cohort study; Dyslipidemia; Lipodystrophy

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; BIOLOGICAL MARKER; EFAVIRENZ; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INDINAVIR; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; ARTICLE; BIOCHEMISTRY; BRAZIL; CASE CONTROL STUDY; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EXPOSURE; DYSLIPIDEMIA; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; MAJOR CLINICAL STUDY; MALE; PREVALENCE; QUESTIONNAIRE; RETROSPECTIVE STUDY; SIDE EFFECT; TERTIARY HEALTH CARE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 60649102288     PISSN: 14138670     EISSN: None     Source Type: Journal    
DOI: 10.1590/s1413-86702008000400002     Document Type: Article

References (28)

1. Carr A., Samaras K., Thorisdottir A., et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and Diabetes mellitus: a cohort study. Lancet 1999;353:2093-9.
2. Chen D., Misra A., Garg A. Lipodystrophy in Human Immunodeficiency Virus-infected patients. J Clin Endocrinol Metab 2002;87:4845-56.
3. Muñoz-Sanz A., Rodriguez-Vidigal F. F., Domingo P. Pathogenesis of lipodistrophy and metabolic syndromes associated with HIV infection. Med Clin (Barc) 2006;127(12):465-74.
4. Wohl D.A., McComsey G., Tebas, P., et al. Current concepts in the diagnosis and management of metabolic complications of HIV infection and its therapy. Clin Infect Dis 2006;43(5):645-53.
5. Lichtenstein K.A., Ward D.J., Moorman A.C., et al. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS 2001;15(11):1389-98.
6. Martinez E., Mocroft A., García-Viejo M.A., et al. Risk of lipodystrophy in HIV-1 infected patients treated with protease inhibitors: a prospective cohort study. Lancet 2001;357:592-8.
7. Haugaard S. B. Toxic metabolic syndrome associated with HAART. Expert Opin Drug Metab Toxicol 2006;2(3):429-45.
8. Duran S., Saves M., Spire B., et al. Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy. AIDS 2001;15:2441-4.
9. Carr A., Samaras K., Burton S., et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12:F51-8.
10. Carr A., Cooper D.A. Images in clinical medicine. Lipodystrophy associated with an HIV-protease inhibitor. N Engl J Med 1998; 339:1296.
11. HIV lipodsytrophy case definition study group. An Objective Case Definition of Lipodystrophy in HIV-Infected Adults: a Case-Control Study. Lancet 2003;361:726-35.
12. Balasubramanyam A., Sekhar R.V., Jahoor F., et al. Pathophysiology of dyslipidemia and increased cardiovascular risk in HIV lipodystrophy: a model for systemic steatosis. Curr Opin Lipidol 2004;15:59-67.
13. Capeau J., Caron M., Vigouroux C., et al. Lipodystrophies related to antiretroviral treatment of HIV infection. Med Sci (Paris) 2006; 22(5):511-6.
14. Santos C.P., Felipe Y.X., Braga P.E., et al. Self-perception of body changes in persons living with HIV/AIDS: prevalence and associated factors. AIDS 2005; Suppl 4:S14-21.
15. Terry L., Sprinz E., Stein R., et al. Exercise training in HIV-1-infected individuals with dyslipidemia and lipodystrophy. Med Sci Sports Exerc 2006;38(3):411-7.
16. b Florindo A. A., de Oliveira Latorre M. do R., Jaime P. C., Segurado A. A. Leisure time physical activity prevents accumulation of central fat in HIV/AIDS subjects on highly active antiretroviral therapy. Int J STD AIDS 2007;18(10):692-6.
17. Sposito A. C., Caramelli B., Sartori A. M., Ramires J.A.F. The lipoprotein profile in HIV infected patients. Braz J Infect Dis 1997;1:275-83.
18. Caramelli B., Bernoche Cysm., Sartori A.M.C., et al. Hyperlipidemia related to the use of HIV-protease inhibitors: natural history and results of treatment with fenofibrate. Braz J Infect Dis 2001; 5:332-8.
19. Albuquerque E.M., de Faria E.C., Oliveira H.C., et al. High frequency of Fredrickson's phenotypes IV and IIb in Brazilians infected by human immunodeficiency virus. BMC Infect Dis 2005;5(1):47.
20. Malavazi I., Abrao E.P., Mikawa A.Y., et al. Abnormalities in apolipoprotein and lipid levels in an HIV-infected Brazilian population under different treatment profiles: the relevance of apolipoprotein E genotypes and immunological status. Clin Chem Lab Med 2004; 42(2):525-32.
21. Lichtenstein K.A., Delaney K.M., Armon C., et al. Incidence of and Risk Factors for Lipoatrophy (Abnormal Fat Loss) in Ambulatory HIV-1 Infected Patients. JAIDS 2003;32:48-56.
22. Pujari S.N., Dravid A., Eknath N., et al. Lipodystrophy and dyslipidemia among patients taking first-line, World Health Organization-recommended highly active antiretroviral therapy regimens in Western India. J Acquir Immune Defic Syndr 2005;39:199.
23. Thaker H.K., Snow M.H. HIV Viral Suppression in the era of antiretroviral therapy. Postgrad Med J 2003;79:36-42.
24. Tien P.C., Grunfeld C. What Is HIV-associated lipodystrophy? Defining fat distribution changes in HIV infection. Curr Opin Infect Dis 2004;17:27-32.
25. Carr A. HIV lipodistrophy: risk factors, pathogenesis, diagnosis and management. AIDS 2003;17(Suppl 1):S141-S8.
26. Mondy K., Tebas P. Cardiovascular risks of antiretroviral therapies. Annu Rev Med 2007;58:141-55.
27. Schwenk A., Breuer P., Kremer G., et al. Clinical Assessment of HIV-Associated Lipodystrophy Syndrome: Bioelectrical Impedance Analysis, Anthropometry and Clinical Scores. Clin Nutr 2001;20:243-9.
28. Grinspoon S., Carr A. Cardiovascular Risk and Body-Fat Abnormalities in HIV-Infected Adults. N Engl J Med 2005;352:48-62.